Enhancing Access to Effective Cancer Medicines Through GIPAP

At Novartis Oncology, we're committed to getting people the care they need today to fight cancer.

We recognize the importance and impact Glivec and other therapies can have on people's lives. Consistent with our vision, we seek to make our innovative medicines broadly available through public-private partnerships and new models that enhance access.

To provide eligible patients with access to Glivec, we developed the Glivec International Patient Assistance Program (GIPAP), one of the most far reaching direct-to-patient donation and support programs ever developed for a cancer medicine. GIPAP helps patients who meet medical and financial criteria: they are not insured, not reimbursed, cannot afford to pay for treatment privately, and are in developing countries with minimal or no reimbursement capabilities. GIPAP care includes support, information, and referral assistance to patients and families. Since 2002, GIPAP has provided more than 26,000 patients in 80 countries with Glivec at no cost.

The Max Foundation (TMF) is our main partner in the administration of GIPAP. TMF provides socio-economic evaluation of patients, guides physicians through a patient evaluation process, and provides emotional support. In response to changing healthcare systems in emerging countries, we identified new ways of enhancing patient access through shared contribution models designed for countries that have the financial ability and/or healthcare infrastructure to provide Glivec treatment to their citizens. By involving governments and other third parties, these models broaden our public-private partnership-based approach to Glivec access and enable governments and payors, including patients, to participate in healthcare treatment and delivery.

Visit the links below for more information.

• www.GIPAP.org
• www.maxaid.org